Cover Story
Free
By Matthew Bin Han Ong
Anil Potti, in a Duke commercial advertising the trial Shoffner joined.Joyce Shoffner would never have predicted that Duke University, an institution she revered and at one time worked for, would put her in a breast cancer clinical trial testing a fraudulent technology.
In Brief
Drugs & Targets
Trending Stories
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Trump 2016: A look back at the 45th president’s impact on oncology